Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy.
Neurocrine axes Takeda-partnered depression program, switches focus for seizure drug after PhII failures
Neurocrine Biosciences has been hit with a pair of mid-stage failures for its partnered candidates in major depressive disorder (MDD) and focal onset seizures (FOS),